Semaglutide News and Research

Latest Semaglutide News and Research

Underwriters Laboratories announces new non-clinical lab, resources and capabilities for biocompatibility in North America

UL (Underwriters Laboratories), a world leader in advancing safety, announced today the expansion of the South Bend, Indiana analytical laboratory to offer non-clinical testing services for the medical device industry.

13 Feb 2013

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Study points to complexity of relationship between sleep duration and energy balance regulation

A new study suggests that increasing the amount of sleep that adults get could lead to reduced food intake, but the hormonal process differs between men and women.

30 Nov 2012

GVK Biosciences receives AERB approvals to carry out 3H and 14C synthesis activities

GVK Biosciences, Asia's leading Drug Discovery Research & Development organization, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C synthesis activities.

19 Nov 2012

Combination of hormones may effectively treat obesity with few side effects

Scientists at Indiana University and international collaborators have found a way to link two hormones into a single molecule, producing a more effective therapy with fewer side effects for potential use as treatment for obesity and related medical conditions.

14 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Some types of bariatric surgery may cause bone loss, say endocrinologists

Bariatric surgery, which significantly curtails the amount of food a person can eat, is the most effective treatment against obesity and is being recognized as a potentially valuable tool in the fight against diabetes related to obesity.

3 Nov 2012

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.

2 Nov 2012

Diabetes drug could treat illicit drug addiction

Researchers have found that a drug currently used to treat Type 2 diabetes could treat addiction to drugs such as cocaine.

26 Oct 2012

Exendin-4 could effectively treat addiction

Vanderbilt researchers are reporting today that a drug currently used to treat type 2 diabetes could be just as effective in treating addiction to drugs, including cocaine.

24 Oct 2012

Positive results from PROLOR's Rpeg preclinical toxicology study

PROLOR Biotech, Inc. today announced positive results from a preclinical toxicology study designed to assess the safety and tolerability of PROLOR's proprietary long-acting reversible-pegylation technology.

17 Oct 2012

DPP-inhibitors reduce cardiovascular events in diabetes patients

Type 2 diabetes patients who are treated with dipeptidyl peptidase-4 inhibitors have a significantly reduced risk for cardiovascular events, particularly myocardial infarction, compared with their peers who take placebo or other drugs, results of a meta-analysis show.

5 Oct 2012

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.

27 Sep 2012

Oxygen Biotherapeutics first quarter net loss increases to $3.6 million

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing intravenous and topical oxygen-carrier products, today announced results for the fiscal year (FY) 2013 first quarter ended July 31, 2012.

20 Sep 2012

Experimental diabetes drug shows promise against Alzheimer's

A drug designed for diabetes sufferers could have the potential to treat neurodegenerative diseases like Alzheimer's, a study by scientists at the University of Ulster has revealed.

15 Sep 2012

Heptares uses StaR technology to solve structure of CRF-1 receptor

Heptares Therapeutics today announces that it has used its StaR technology to solve entirely in-house the first structure of a Family B sub-class G protein-coupled receptor (GPCR).

10 Sep 2012

BioReliance introduces Reconstructed Skin Micronucleus Assay to detect DNA damage

Sigma-Aldrich Corporation today announced that its recent acquisition, BioReliance, the biopharma and early development services business under SAFC, will introduce a new assay to detect DNA damage from products with dermal routes of exposure. The Reconstructed Skin Micronucleus (RSMN) Assay represents the first commercial offering of a Genetic Toxicology assay using three-dimensional tissue models.

5 Sep 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Quintiles acquires premier provider of genomics testing and analysis

To help biopharmaceutical companies dramatically improve drug development productivity and deliver greater value, Quintiles today announced the acquisition of Expression Analysis, Inc. (EA), a premier provider of genomics testing and analysis to biopharma, academic, government and non-profit customers.

13 Aug 2012